Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Menlo Therapeutics Inc (MNLO)

Menlo Therapeutics Inc (MNLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Menlo Therapeutics Inc 520 U.S. HIGHWAY 22 SUITE 204 BRIDGEWATER NJ 08807 USA

www.menlotherapeutics.com P: 800-775-7936

Description:

Menlo Therapeutics Inc. is a late stage biopharmaceutical company. It focused on the development of serlopitant and treatment of chronic itch and chronic refractory cough. The company's product pipeline consists of Prurigo Nodularis Itch, Atopic Dermatitis Itch, Psoriasis Itch and Refractory Chronic Cough which are in clinical stage. Menlo Therapeutics Inc. is headquartered in Redwood City, California.

Key Statistics

Overview:

Market Capitalization, $K 226,383
Shares Outstanding, K 167,691
Annual Sales, $ 0 K
Annual Net Income, $ -73,700 K
Last Quarter Sales, $ 11,690 K
Last Quarter Net Income, $ -167,440 K
60-Month Beta 1.07
% of Insider Shareholders 2.20%
% of Institutional Shareholders 50.07%
Float, K 164,002
% Float 97.80%

Growth:

1-Year Return -71.99%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 10/29/20
Earnings Per Share ttm -3.75
EPS Growth vs. Prev Qtr -27.37%
EPS Growth vs. Prev Year -75.36%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MNLO Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -331.83%
Return-on-Assets % -210.67%
Profit Margin % 0.00%
Debt/Equity 0.46
Price/Sales 16.84
Price/Cash Flow N/A
Price/Book 3.16
Book Value/Share 0.43
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar